| Product Code: ETC13280538 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Lung Cancer Liquid Biopsy Market was valued at USD 2.6 Billion in 2024 and is expected to reach USD 4.5 Billion by 2031, growing at a compound annual growth rate of 5.80% during the forecast period (2025-2031).
The Global Lung Cancer Liquid Biopsy Market is experiencing rapid growth primarily driven by the rising prevalence of lung cancer worldwide and the increasing demand for non-invasive diagnostic methods. Liquid biopsy offers advantages such as early detection, real-time monitoring of disease progression, and personalized treatment decisions. Key players in the market are investing in research and development to introduce innovative liquid biopsy tests for lung cancer detection and monitoring. The market is also witnessing collaborations between pharmaceutical companies and diagnostic firms to enhance the development and commercialization of liquid biopsy technologies. Additionally, the growing awareness among healthcare professionals and patients regarding the benefits of liquid biopsy in lung cancer management is further propelling market expansion.
The Global Lung Cancer Liquid Biopsy Market is experiencing significant growth due to the increasing adoption of liquid biopsy techniques for non-invasive cancer diagnosis and monitoring. Key trends include the development of advanced liquid biopsy technologies for early detection of lung cancer, the rising prevalence of lung cancer cases worldwide, and the growing demand for personalized medicine in oncology. Opportunities in the market lie in the expansion of liquid biopsy applications beyond traditional diagnostics to include treatment response monitoring, minimal residual disease detection, and drug resistance profiling. Additionally, collaborations between pharmaceutical companies and diagnostic firms are driving innovation and product development in the lung cancer liquid biopsy market. Overall, the market is poised for continued growth as healthcare providers seek more efficient and accurate methods for managing lung cancer patients.
The Global Lung Cancer Liquid Biopsy Market faces several challenges, including regulatory hurdles, reimbursement issues, and the need for standardization and validation of liquid biopsy tests. Regulatory approval processes can be lengthy and costly, hindering the adoption of liquid biopsy techniques. Reimbursement policies for liquid biopsy tests vary across different regions, creating uncertainty for healthcare providers and patients. Additionally, the lack of standardized protocols and guidelines for the collection, analysis, and interpretation of liquid biopsy results poses a challenge in ensuring the accuracy and reliability of these tests. Overcoming these challenges will be essential for the widespread acceptance and integration of liquid biopsy technology in lung cancer diagnosis and treatment.
The Global Lung Cancer Liquid Biopsy Market is primarily driven by the increasing prevalence of lung cancer cases worldwide, leading to a growing demand for non-invasive diagnostic tools. Liquid biopsy offers advantages such as early detection, monitoring of treatment response, and identification of drug resistance mutations, driving its adoption in clinical settings. Additionally, advancements in technology, such as next-generation sequencing and digital PCR, have improved the sensitivity and accuracy of liquid biopsy tests, further fueling market growth. The rising focus on personalized medicine and targeted therapies in lung cancer treatment also contributes to the market expansion, as liquid biopsy enables the identification of specific genetic alterations for tailored treatment strategies. Moreover, the potential cost-effectiveness and convenience of liquid biopsy compared to traditional tissue biopsies are attracting both healthcare providers and patients, driving market momentum.
Government policies related to the Global Lung Cancer Liquid Biopsy Market typically focus on regulatory oversight, reimbursement policies, and funding for research and development. Regulatory bodies such as the FDA in the US and the EMA in Europe play a crucial role in ensuring the safety and efficacy of liquid biopsy tests for lung cancer. Reimbursement policies impact the adoption of these tests by healthcare providers and insurers, with some countries offering coverage for liquid biopsy procedures. Additionally, government funding for research in the field of liquid biopsy technology is essential for driving innovation and expanding the market. Overall, government policies aim to create a supportive regulatory environment, incentivize investment, and promote the use of liquid biopsy tests in the diagnosis and monitoring of lung cancer patients.
The Global Lung Cancer Liquid Biopsy Market is expected to witness significant growth in the coming years due to the increasing prevalence of lung cancer cases worldwide. Liquid biopsy offers a non-invasive and convenient method for early detection, monitoring treatment response, and detecting resistance mutations in lung cancer patients. The market is projected to expand as advancements in technology lead to more accurate and sensitive liquid biopsy tests, driving adoption among healthcare providers and patients. Additionally, the rising demand for personalized medicine and targeted therapies in lung cancer treatment is expected to further propel the market growth. Overall, the Global Lung Cancer Liquid Biopsy Market is anticipated to experience substantial growth opportunities in the foreseeable future.
The Global Lung Cancer Liquid Biopsy Market shows promising growth potential across various regions. In Asia, the market is driven by the rising prevalence of lung cancer and increasing adoption of advanced diagnostic technologies. North America leads in market share due to robust healthcare infrastructure and high investment in research and development. Europe is witnessing significant growth attributed to the increasing awareness about the benefits of liquid biopsy in early cancer detection. The Middle East and Africa region is expected to experience steady growth with improving healthcare facilities and rising investments in oncology diagnostics. Latin America is also showing growth opportunities with the increasing focus on personalized medicine and the adoption of liquid biopsy for lung cancer detection.
Global Lung Cancer Liquid Biopsy Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Lung Cancer Liquid Biopsy Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 & 2031F |
3.3 Global Lung Cancer Liquid Biopsy Market - Industry Life Cycle |
3.4 Global Lung Cancer Liquid Biopsy Market - Porter's Five Forces |
3.5 Global Lung Cancer Liquid Biopsy Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Lung Cancer Liquid Biopsy Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.7 Global Lung Cancer Liquid Biopsy Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Global Lung Cancer Liquid Biopsy Market Revenues & Volume Share, By End-User, 2021 & 2031F |
4 Global Lung Cancer Liquid Biopsy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Lung Cancer Liquid Biopsy Market Trends |
6 Global Lung Cancer Liquid Biopsy Market, 2021 - 2031 |
6.1 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By CTC (Circulating Tumor Cells), 2021 - 2031 |
6.1.3 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By ctDNA (Circulating tumor DNA), 2021 - 2031 |
6.1.4 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Exosomes and RNA, 2021 - 2031 |
6.2 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Small Cell Lung Cancer, 2021 - 2031 |
6.2.3 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Non-Small Cell Lung Cancer, 2021 - 2031 |
6.3 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Diagnostic and Imaging Centres, 2021 - 2031 |
6.3.3 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.3.4 Global Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Academic and Research Centers, 2021 - 2031 |
7 North America Lung Cancer Liquid Biopsy Market, Overview & Analysis |
7.1 North America Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 - 2031 |
7.2 North America Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
7.4 North America Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5 North America Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
8 Latin America (LATAM) Lung Cancer Liquid Biopsy Market, Overview & Analysis |
8.1 Latin America (LATAM) Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
8.4 Latin America (LATAM) Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
8.5 Latin America (LATAM) Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
9 Asia Lung Cancer Liquid Biopsy Market, Overview & Analysis |
9.1 Asia Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
9.4 Asia Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
9.5 Asia Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
10 Africa Lung Cancer Liquid Biopsy Market, Overview & Analysis |
10.1 Africa Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
10.4 Africa Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
10.5 Africa Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
11 Europe Lung Cancer Liquid Biopsy Market, Overview & Analysis |
11.1 Europe Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
11.4 Europe Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
11.5 Europe Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
12 Middle East Lung Cancer Liquid Biopsy Market, Overview & Analysis |
12.1 Middle East Lung Cancer Liquid Biopsy Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Lung Cancer Liquid Biopsy Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
12.4 Middle East Lung Cancer Liquid Biopsy Market, Revenues & Volume, By Application, 2021 - 2031 |
12.5 Middle East Lung Cancer Liquid Biopsy Market, Revenues & Volume, By End-User, 2021 - 2031 |
13 Global Lung Cancer Liquid Biopsy Market Key Performance Indicators |
14 Global Lung Cancer Liquid Biopsy Market - Export/Import By Countries Assessment |
15 Global Lung Cancer Liquid Biopsy Market - Opportunity Assessment |
15.1 Global Lung Cancer Liquid Biopsy Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Lung Cancer Liquid Biopsy Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
15.3 Global Lung Cancer Liquid Biopsy Market Opportunity Assessment, By Application, 2021 & 2031F |
15.4 Global Lung Cancer Liquid Biopsy Market Opportunity Assessment, By End-User, 2021 & 2031F |
16 Global Lung Cancer Liquid Biopsy Market - Competitive Landscape |
16.1 Global Lung Cancer Liquid Biopsy Market Revenue Share, By Companies, 2024 |
16.2 Global Lung Cancer Liquid Biopsy Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |